Double down for a double win.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 22392916.
- Also identified by DOI 10.1158/1078-0432.CCR-12-0461.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The rationale for using multiple inhibitors between and within the phosphoinositide 3-kinase/AKT/mTOR and RAS/MEK/ERK pathways is scientifically compelling, and a limited number of experimental agents are currently being tested in phase I combinations. Patient subpopulations, whose tumors are defined by genetic lesions, are showing promising responses to this approach.
Medical subject headings
- MAP Kinase Signaling System
- Neoplasms